Researchers said the first COVID-19 vaccine tested in the U.S. elicited a response from the human immune system just as scientists had hoped. Vaccine from the National Institute of Health and Moderna Inc. transferred to the second phase of testing – final tests.
“This is really good news,” said Dr. Anthony Fochi, chief expert on infectious diseases in the US government. The second series of vaccine tests will begin on July 27, and 30,000 people will be accepted.
But the first results of testing on 45 volunteers showed that the vaccine is safe and effective. The first group of participants in the blood revealed the so-called neutralizing antibodies – molecules that are the key to blocking infection – at levels comparable to those found in people who survived COVID-19. No serious side effects were detected. But more than half of the study participants reported flu-like reactions to vaccines, which are not uncommon when using other vaccines.
This vaccine provides for the introduction of two injections at intervals of a month.
The results are published in the New England Journal of Medicine.